Today, the CEO of CymaBay Therapeutics (NASDAQ: CBAY), Sujal Shah, bought shares of CBAY for $53.25K.
This recent transaction increases Sujal Shah’s holding in the company by 5.88% to a total of $1.05 million. Following Sujal Shah’s last CBAY Buy transaction on July 24, 2017, the stock climbed by 3.7%.
See today’s analyst top recommended stocks >>
Currently, CymaBay Therapeutics has an average volume of 907.6K.
Starting in January 2017, CBAY received 49 Buy ratings in a row. Based on 8 analyst ratings, the analyst consensus is Strong Buy with an average price target of $19.86, reflecting a -41.2% downside. Nine different firms, including Cantor Fitzgerald and Evercore ISI, currently also have a Buy rating on the stock.
The insider sentiment on CymaBay Therapeutics has been negative according to 23 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CymaBay Therapeutics, Inc. is a clinical stage company, which engages in the research and development of biopharmaceutical products. Its candidates include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid.
Read More on CBAY:
